Placebo Comparator

Phase 3

UUniversity of Arizona

Placebo Comparator is one of 57 therapeutic programs targeting Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

MigraineRecruiting

SchizophreniaActive, not recruiting

Muscle RelaxantsCompleted

MigrainePhase 3

Recruiting

SchizophreniaPhase 1

Active, not recruiting

Muscle RelaxantsPreclinical

Completed

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Placebo Comparator

UUniversity of Arizona

Phase 3

1 2

Celexa

AbbVie

Preclinical

4 3

Zocor

OOrganon and Co

Preclinical

6 4

Depakote

Ibrance

Lunesta

3 7

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Schizophrenia

NCT03781115

Phase 3Recruiting

Migraine

NCT06641466

Clinical

Trials by Indication[1]

Migraine1 trial

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06641466·723 enrolled

Muscle Relaxants1 trial

Effect of Ulinastatin on the Action of Nondepolarising Muscle Relaxants Rocuronium / Cisatracurium

Completed·HHuazhong University of Science and Technology·Preclinical·NCT05716256·120 enrolled

Schizophrenia1 trial

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Active, not recruiting·UUniversity of Arizona·Phase 1·NCT03781115·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Placebo Comparator. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Comparator. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Arizona

Placebo Comparator

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Migraine1 trial

Muscle Relaxants1 trial

Schizophrenia1 trial

References

Drug Info

Quick Facts

Related News